Drugs / Clopidogrel
Clopidogrel
also known as
Plavix · Clopidogrel: Plavix · Clopidogrel Bisulfate · SR25990 · Plavix (clopidogrel) · SR25990C · Iscover · A brand name for clopidogrel is PLAVIX. · +14 more
Small molecule targets CYP2C8, P2RY12 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | PLAVIX | — | 2002-02-27 – 2011-05-06 | fda.gov ↗ |
| Approved | EU (EMA) | Iscover | — | 1998-07-14 | europa.eu ↗ |
| Approved | US (FDA) | PLAVIX | — | 1997-11-17 | fda.gov ↗ |
Trials 324 · started per year
today
US approved 1997
EU approved 1998
3
1
5
7
10
5
12
9
17
22
18
12
12
20
11
13
15
13
15
15
10
10
14
18
12
14
9
19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT06933056 | Sep 2025 → Sep 2026 overdue | — | University of Michigan | Recruiting | No outcome recorded |
| Phase 0 | NCT06692933 | Jun 2024 → Aug 2027 expected | — | Washington State University | Recruiting | No outcome recorded |
| Phase 0 | NCT06339021 | Apr 2024 → Dec 2026 expected | ST-elevation myocardial infarction | Shenyang Northern Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04822363 | Aug 2021 → May 2025 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 148 trials · 2 met primary | ||||||
| Phase 1 | NCT07265466 | Nov 2025 → Mar 2026 overdue | — | Onconic Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07040787 | Jul → Aug 2025 | glomerulonephritis, hemolytic anemia | Chengdu Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06584812 | Sep → Dec 2024 | acute coronary syndrome, ischemic stroke | Tianjin Institute of Pharmaceutical Research Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06164834 | Dec 2023 → Nov 2024 | — | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT05574374 | Sep 2022 → Mar 2023 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT05162053 | Dec 2021 → Nov 2022 | acute coronary syndrome | Jiangsu vcare pharmaceutical technology co., LTD | Completed | No outcome recorded |
| Phase 1 | NCT04809818 | Mar → Aug 2021 | ischemic stroke | Lumosa Therapeutics Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04305587 | Mar 2020 → Jul 2021 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04171687 | Oct 2019 → Feb 2020 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03814642 | Jan → Jul 2019 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03698513 | Oct 2018 → Feb 2019 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03245489 | Mar 2018 → Nov 2023 | head and neck cancer | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1 | NCT03496506 | Mar → May 2018 | — | Actelion | Completed | No outcome recorded |
| Phase 1 | NCT03430661 | Jan 2018 → May 2019 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03392051 | Dec 2017 → Mar 2018 | cardiovascular disorder, hyperlipoproteinemia | Akcea Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03471169 | Apr 2017 → Dec 2018 | cerebrovascular disorder | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
| Phase 1 | NCT02922465 | Sep → Oct 2016 | — | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02560688 | Dec 2015 → Mar 2016 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02554721 | Aug 2015 → Mar 2018 | — | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03054207 | Jun 2015 → Apr 2017 | HIV infectious disease | Jules Desmeules | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02010632 | Aug 2013 → Oct 2014 | — | Khon Kaen University | Completed | No outcome recorded |
| Phase 1 | NCT01768637 | Jan 2013 → Apr 2014 | chronic kidney disease | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01469416 | Mar 2012 → May 2013 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01263093 | Dec 2010 → Mar 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01210339 | Nov 2010 → Aug 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01557335 | Nov 2010 → Feb 2011 | platelet aggregation, spontaneous | POZEN | Completed | Met primary |
| Phase 1 | NCT01108588 | Jun → Aug 2010 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01147588 | May 2010 → May 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00942175 | Dec 2009 → Jun 2010 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT00989300 | Nov 2009 → Mar 2010 | — | Janssen Cilag S.A.S. | Completed | No outcome recorded |
| Phase 1 | NCT01129427 | Aug → Nov 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01129414 | Jun → Aug 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01123824 | Apr → Aug 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01409616 | Apr → Sep 2009 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT01129271 | Apr → Jun 2009 | — | Sanofi | Completed | Met primary |
| Phase 1 | NCT01129063 | Mar → May 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01129388 | Mar → May 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02171598 | Feb → Jul 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01129375 | Feb → May 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01447563 | May → Jun 2008 | — | Hospital Universitario Dr. Jose E. Gonzalez | Terminated | No outcome recorded |
| Phase 1 | NCT01603342 | Dec 2007 → Jan 2008 | vascular hemostatic disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00696566 | Nov 2007 → Mar 2008 | coronary artery disorder | Sheffield Teaching Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1 | NCT00413608 | Jan 2007 → Jan 2009 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1 | NCT00363753 | Aug 2006 → Mar 2007 | aspirin resistance, transient ischemic attack | University of California, San Diego | Withdrawn | No outcome recorded |
| Phase 1 | NCT00648947 | Dec 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT02262650 | Apr → May 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02222987 | Feb → Mar 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02265289 | Jan → Feb 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04168398 | Jul 2019 → Nov 2021 | limb ischemia | Mansoura University | Completed | No outcome recorded |
| Phase 1/2 | NCT02320357 | Aug 2015 → Sep 2017 | systemic lupus erythematosus | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 224 trials · 3 met primary · 4 missed | ||||||
| Phase 2 | NCT07384702 | Jun 2026 → Jun 2030 expected | staphylococcus aureus infection | Andalusian Public Foundation for Health Research in Seville | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06638151 | Sep 2025 → Jul 2026 | ischemic stroke | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT07844603 | Sep 2025 → Jul 2026 | ischemic stroke | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT05567562 | Mar 2024 → Feb 2025 | pulmonary emphysema | Brigham and Women's Hospital | Completed | Missed primary |
| Phase 2 | NCT05926271 | Jul 2023 → Jun 2026 overdue | acute coronary syndrome | St. Antonius Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05546320 | Oct 2022 → Mar 2025 | migraine disorder, patent foramen ovale | Chinese Academy of Medical Sciences, Fuwai Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04824911 | Mar 2021 → Feb 2025 | stroke disorder | Chang Gung Memorial Hospital | Completed | Met primary |
| Phase 2 | NCT03606642 | Nov 2018 → Dec 2021 | atherosclerosis, coronary artery disorder | HonorHealth Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT02565693 | Sep 2014 → Jan 2021 | atrial fibrillation, intracerebral hemorrhage | UMC Utrecht | Completed | Missed primary |
| Phase 2 | NCT01979445 | Dec 2013 → Jan 2014 | coronary artery disorder | The Medicines Company | Completed | No outcome recorded |
| Phase 2 | NCT01955512 | May 2013 → May 2014 | asthma | University of Southampton | Completed | No outcome recorded |
| Phase 2 | NCT02285751 | Nov 2012 → Jul 2020 | critical illness polyneuropathy | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2 | NCT01738100 | Sep 2012 → Dec 2016 | ST-elevation myocardial infarction | Hyeon-Cheol Gwon | Unknown | Missed primary |
| Phase 2 | NCT01960296 | Jan 2012 → May 2013 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT01115738 | May 2010 → Nov 2011 | acute coronary syndrome | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT00940784 | Jun 2009 → Jan 2011 | acquired polycythemia vera | Ronald Hoffman | Withdrawn | No outcome recorded |
| Phase 2 | NCT01103440 | Apr 2007 → Jun 2009 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT00357968 | Aug 2006 → Jun 2007 | coronary artery disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00356135 | Jul 2006 → Dec 2008 | acute coronary syndrome, arteriosclerosis disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 2 | NCT00263211 | Jan 2006 → Sep 2009 | breast cancer | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT00360386 | Mar 2004 → Feb 2005 | ischemic disease | Sanofi | Completed | Met primary |
| Phase 2 | NCT00115375 | Jan 2004 → Apr 2006 | blood platelet disease, congenital heart defects, multiple types | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00406991 | Jun 2003 → Mar 2006 | diabetes mellitus, diabetic retinopathy | Schepens Eye Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00105209 | Apr 2002 → Dec 2003 | pulmonary arterial hypertension | Kawut, Steven, MD | Completed | No outcome recorded |
| Phase 2/39 trials · 1 missed | ||||||
| Phase 2/3 | NCT05657041 | Apr 2023 → Aug 2024 | coronary artery disorder | St. Antonius Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT05098704 | Jun 2022 → Jun 2032 expected | systemic sclerosis | University Hospital, Bordeaux | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05122455 | Sep 2021 → Jun 2024 | — | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2/3 | NCT04491695 | Sep 2020 → Dec 2022 | stroke disorder | Capital Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02048228 | Oct 2014 → Mar 2016 | — | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02044146 | Sep 2014 → Oct 2016 | acute coronary syndrome | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 2/3 | NCT01894789 | Mar 2013 → Mar 2015 | coronary artery disorder | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 2/3 | NCT01184300 | Aug 2010 → Jul 2011 | acute coronary syndrome, coronary artery disorder | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 2/3 | NCT00109382 | May 2003 → Feb 2007 | transient ischemic attack | University of Calgary | Completed | Missed primary |
| Phase 354 trials · 8 met primary · 7 missed | ||||||
| Phase 3 | NCT07512960 | Jun 2026 → May 2030 expected | — | Fondation Hôpital Saint-Joseph | Recruiting | No outcome recorded |
| Phase 3 | NCT07012629 | Nov 2025 → Sep 2031 expected | MRI defined brain infarct | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06853535 | May 2025 → Jun 2027 expected | ischemic stroke | Sichuan Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06165068 | Dec 2023 → Dec 2025 overdue | dry age related macular degeneration | Navamindradhiraj University | Recruiting | No outcome recorded |
| Phase 3 | NCT05952206 | Oct 2023 → Jan 2027 expected | coronary artery disorder | iVascular S.L.U. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06021990 | Oct 2023 → Sep 2024 | chronic obstructive pulmonary disease | Lady Reading Hospital, Pakistan | Unknown | No outcome recorded |
| Phase 3 | NCT05387954 | Jul 2023 → Jul 2031 expected | ischemic stroke, patent foramen ovale | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT05903976 | Jun 2023 → Jun 2025 | acute coronary syndrome, coronary artery disorder | Azienda Ospedaliera Universitaria Policlinico "G. Martino" | Unknown | No outcome recorded |
| Phase 3 | NCT02433587 | Oct 2019 → Jul 2021 | peripheral arterial disease | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03357874 | Oct 2018 → Jan 2023 | acute coronary syndrome | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT03635749 | Sep 2018 → Jan 2023 | transient ischemic attack | Beijing Tiantan Hospital | Unknown | Mixed |
| Phase 3 | NCT03001960 | Mar 2017 → Mar 2018 | aortic valve stenosis, intracranial embolism | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 3 | NCT02966119 | Dec 2016 → Dec 2019 | intracerebral hemorrhage | University Hospital, Lille | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02869009 | Nov 2016 → Oct 2022 | ischemic stroke | General Hospital of Shenyang Military Region | Completed | Met primary |
| Phase 3 | NCT02944123 | Sep 2016 → Feb 2020 | acute coronary syndrome | Dong-A University | Completed | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT02404363 | Jan 2016 → Dec 2017 | pancreatic adenocarcinoma | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02798913 | Jan 2016 → Jun 2020 | peripheral arterial disease | Federico II University | Unknown | No outcome recorded |
| Phase 3 | NCT02217501 | Nov 2015 → Jan 2020 | peripheral arterial disease | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01763320 | Mar 2014 → Nov 2016 | ischemic stroke | Xuanwu Hospital, Beijing | Completed | Missed primary |
| Phase 3 | NCT02086903 | Feb → Apr 2014 | — | Dong-A University | Completed | No outcome recorded |
| Phase 3 | NCT01961856 | Sep 2013 → Feb 2014 | — | University of Patras | Completed | No outcome recorded |
| Phase 3 | NCT01805596 | Apr 2013 → Feb 2016 | coronary artery disorder | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 3 | NCT01778842 | Mar → Jun 2013 | coronary artery disorder | Gennaro Sardella | Unknown | No outcome recorded |
| Phase 3 | NCT01812330 | Jan 2013 → Dec 2015 | acute coronary syndrome | General Hospital of Chinese Armed Police Forces | Unknown | No outcome recorded |
| Phase 3 | NCT02163954 | Jan → Aug 2013 | chronic kidney disease | Kyunghee University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01543932 | Jul 2012 → Dec 2013 | coronary artery disorder | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 3 | NCT01505790 | Jul 2011 → May 2012 | acute coronary syndrome | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT01598337 | Apr 2011 → Dec 2013 | coronary artery disorder | Prince Sultan Cardiac Center, Adult Cardiology Department. | Unknown | No outcome recorded |
| Phase 3 | NCT00944333 | Jul 2009 → Jun 2014 | intermediate coronary syndrome, ischemic disease | Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS | Terminated | Met primary |
| Phase 3 | NCT00889044 | Apr 2009 → Dec 2010 | platelet aggregation, spontaneous | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00862420 | Feb 2009 → May 2011 | peripheral arterial disease | Sanofi | Completed | Met primary |
| Phase 3 | NCT00833703 | Jan 2009 → Jul 2010 | congenital heart disease | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00821834 | Dec 2008 → Aug 2010 | coronary artery disorder, myocardial infarction | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01046942 | Nov 2008 → May 2014 | thrombophilia, thrombotic disease | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase 3 | NCT00822666 | Oct 2008 → Dec 2009 | coronary artery disorder | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01032668 | Sep 2008 → Jul 2009 | coronary artery disorder | Bursa Postgraduate Hospital | Completed | Met primary |
| Phase 3 | NCT00638326 | Mar 2008 → Sep 2009 | coronary artery disorder | University of Pecs | Terminated | Met primary |
| Phase 3 | NCT00776477 | Dec 2007 → Dec 2008 | atherosclerosis | China National Center for Cardiovascular Diseases | Unknown | Met primary |
| Phase 3 | NCT00396877 | Nov 2006 → Feb 2010 | congenital heart disease | Sanofi | Completed | Missed primary |
| Phase 3 | NCT00330772 | Jul 2006 → Jun 2008 | coronary artery disorder | Hamilton Health Sciences Corporation | Completed | Missed primary |
| Phase 3 | NCT00335452 | Jun 2006 → Sep 2009 | acute coronary syndrome, intermediate coronary syndrome | Sanofi | Completed | Mixed |
| Phase 3 | NCT00305162 | Apr 2006 → May 2009 | acute coronary syndrome, myocardial infarction | The Medicines Company | Terminated | Missed primary |
| Phase 3 | NCT00444132 | Mar 2005 → Jun 2007 | — | Sheba Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00174759 | Sep 2004 → ? | arterial occlusion | Sanofi | Completed | Missed primary |
| Phase 3 | NCT00693069 | Sep 2004 → Apr 2006 | coronary artery disorder | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Completed | No outcome recorded |
| Phase 3 | NCT00325390 | Jul 2004 → ? | acute coronary syndrome, platelet aggregation, spontaneous | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00716924 | May 2004 → Feb 2006 | thrombotic disease | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00243178 | Jul 2003 → Sep 2005 | atrial fibrillation, vascular disorder | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT00249873 | Jun 2003 → Mar 2009 | atrial fibrillation, vascular disorder | Sanofi | Completed | Met primary |
| Phase 3 | NCT00714961 | Feb 2003 → Jan 2005 | acute coronary syndrome | Sanofi | Completed | Met primary |
| Phase 3 | NCT03289520 | Jan 2003 → Jun 2007 | kidney failure | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 3 | NCT00050817 | Oct 2002 → Aug 2005 | arteriosclerosis disorder | Sanofi | Completed | Missed primary |
| Phase 3 | NCT00235248 | Feb 2002 → Dec 2010 | brain infarction, transient ischemic attack | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 4138 trials · 20 met primary · 16 missed | ||||||
| Phase 4 | NCT07602257 | Oct 2026 → Dec 2029 expected | — | Ottawa Heart Institute Research Corporation | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07644234 | Jun 2026 → Dec 2028 expected | transient ischemic attack | Sichuan Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07592507 | May 2026 → Feb 2032 expected | coronary artery disorder | Daejeon St. Mary's hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06650488 | Jan 2026 → Jan 2030 expected | infective endocarditis, staphylococcus aureus infection | Todd C. Lee MD MPH FIDSA | Recruiting | No outcome recorded |
| Phase 4 | NCT07237308 | Dec 2025 → Jul 2029 expected | atrial fibrillation, intracranial arteriosclerosis, ischemic disease, stroke disorder | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07025148 | Oct 2025 → Aug 2027 expected | coronary artery disorder | University of Florida | Recruiting | No outcome recorded |
| Phase 4 | NCT07111559 | Aug 2025 → Mar 2028 expected | brain small vessel disease 4, ischemic stroke | Nippon Medical School | Recruiting | No outcome recorded |
| Phase 4 | NCT06588595 | Nov 2024 → Aug 2027 expected | coronary artery disorder | University of Florida | Recruiting | No outcome recorded |
| Phase 4 | NCT06613191 | Oct 2024 → Dec 2025 overdue | coronary artery disorder, peripheral vascular disease | Ochsner Health System | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06402747 | Apr 2024 → Dec 2026 expected | atherosclerosis, type 2 diabetes mellitus | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| Show all 138 trials opens the full record — a long page | ||||||
| Phase not applicable44 trials · 3 met primary | ||||||
| — | NCT07587099 | May 2026 → Dec 2029 expected | coronary artery disorder | Gan Lijun | Recruiting | No outcome recorded |
| — | NCT07432516 | Feb 2026 → Jun 2033 expected | coronary artery disorder | Yonsei University | Not yet recruiting | No outcome recorded |
| — | NCT06535568 | Jan 2026 → Jan 2028 expected | acute coronary syndrome, arterial occlusion, atherosclerosis, coronary stenosis | Fondazione Ricerca e Innovazione Cardiovascolare ETS | Recruiting | No outcome recorded |
| — | NCT06714526 | Oct 2025 → Aug 2027 expected | cerebral atherosclerosis | Sunnybrook Health Sciences Centre | Recruiting | No outcome recorded |
| — | NCT07198529 | Sep 2025 → Sep 2029 expected | coronary artery disorder | Korea University Guro Hospital | Recruiting | No outcome recorded |
| — | NCT07613840 | Apr 2025 → Apr 2027 expected | peripheral arterial disease, thrombotic disease | Massachusetts General Hospital | Recruiting | No outcome recorded |
| — | NCT06866665 | Mar 2025 → Dec 2030 expected | atrial fibrillation, coronary artery disorder | Yonsei University | Not yet recruiting | No outcome recorded |
| — | NCT06276374 | Jul 2024 → Nov 2029 expected | carotid artery disorder | Woo-Keun Seo | Recruiting | No outcome recorded |
| — | NCT06424548 | May 2024 → Jun 2028 expected | atherosclerosis, ischemic stroke | Ewha Womans University Seoul Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06175377 | Mar 2024 → Mar 2027 expected | arterial occlusion | Assistance Publique Hopitaux De Marseille | Not yet recruiting | No outcome recorded |
| — | NCT05761704 | Nov 2023 → Nov 2024 | atrial fibrillation | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT06058130 | Sep 2023 → Oct 2025 | atrial fibrillation, carotid stenosis, intracranial arteriosclerosis, ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT06053021 | Sep 2023 → Oct 2025 | ischemic stroke, thrombocytopenia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT05825391 | May → Oct 2023 | brain aneurysm | Beijing Tiantan Hospital | Completed | Met primary |
| — | NCT05493657 | Feb 2023 → Jul 2026 overdue | aortic valve stenosis | Yonsei University | Recruiting | No outcome recorded |
| — | NCT05623904 | Oct 2022 → Dec 2025 | carotid stenosis | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
| — | NCT05353140 | Sep 2022 → Sep 2028 expected | atrial fibrillation | Xijing Hospital | Recruiting | No outcome recorded |
| — | NCT05320926 | Jul 2022 → Jul 2028 expected | ischemic disease | Yonsei University | Recruiting | No outcome recorded |
| — | NCT04995159 | Sep 2021 → Jan 2026 overdue | coronary artery disorder | Lepu Medical Technology (Beijing) Co., Ltd. | Not yet recruiting | No outcome recorded |
| — | NCT04948749 | Jul 2021 → Dec 2027 expected | intracranial arteriosclerosis, stroke disorder | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT07597239 | Nov 2020 → Feb 2026 overdue | arterial occlusion, peripheral arterial disease, thrombotic disease | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| — | NCT04333407 | Apr 2020 → Nov 2021 | COVID-19 | Imperial College London | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT03266731 | Jan 2018 → Jan 2019 | ischemic stroke | Assiut University | Unknown | No outcome recorded |
| — | NCT03111420 | Jan 2017 → Jun 2018 | platelet disorder, undefined | Aggredyne, Inc. | Completed | No outcome recorded |
| — | NCT02696226 | Feb 2016 → Jul 2017 | aortic valve disorder | The Cleveland Clinic | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02865824 | Jan 2016 → Dec 2018 | polyp of colon | Incheon St.Mary's Hospital | Unknown | No outcome recorded |
| — | NCT02244710 | Mar 2015 → Sep 2016 | acute coronary syndrome | Fundación Investigación Sanitaria en León | Completed | No outcome recorded |
| — | NCT02079194 | Mar 2014 → Jul 2018 | coronary artery disorder | Samsung Medical Center | Unknown | Met primary |
| — | NCT01701453 | Aug 2012 → Nov 2017 | acute coronary syndrome | Samsung Medical Center | Unknown | Met primary |
| — | NCT02707445 | Sep 2011 → Feb 2016 | myocardial ischemia | Korea University Anam Hospital | Completed | No outcome recorded |
| — | NCT01233167 | Aug 2011 → Dec 2012 | coronary artery disorder | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| — | NCT03759067 | Oct 2010 → Jan 2012 | intermediate coronary syndrome | Korea University Anam Hospital | Completed | No outcome recorded |
| — | NCT01341600 | Jul 2010 → May 2011 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT01264640 | Jul 2010 → Feb 2011 | — | University of Rostock | Unknown | No outcome recorded |
| — | NCT02384070 | Jan 2009 → Dec 2013 | coronary artery disorder | Odessa Heart Institute | Completed | No outcome recorded |
| — | NCT01212302 | Oct 2008 → Mar 2010 | coronary artery disorder | Ruhr University of Bochum | Completed | No outcome recorded |
| — | NCT00781573 | Sep 2008 → Mar 2014 | myocardial infarction | North Texas Veterans Healthcare System | Completed | No outcome recorded |
| — | NCT00620646 | Feb → Dec 2008 | — | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT00644657 | Mar 2007 → Sep 2008 | intermediate coronary syndrome | University of Oklahoma | Completed | No outcome recorded |
| — | NCT00418860 | Sep 2006 → Apr 2008 | coronary artery disorder | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT00302913 | Dec 2005 → Jun 2006 | coronary artery disorder | University Heart Center Freiburg - Bad Krozingen | Completed | No outcome recorded |
| — | NCT00494156 | Jul 2003 → Jul 2008 | arterial disorder | C. Clay Cothren, MD | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00262275 | Jul 2002 → Jul 2004 | ischemic disease | Papworth Hospital NHS Foundation Trust | Completed | Mixed |
| — | NCT00004564 | — | hyperlipidemia, thrombotic disease | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT00839345 | — | coronary artery disorder | Charles University, Czech Republic | Temporarily not available | No outcome recorded |
| Comparator or background therapy490 trials | ||||||
| Phase 0 | NCT00797056 Background | Apr 2008 → Apr 2012 | peripheral vascular disease | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT07619885 Comparator | Jun → Oct 2026 expected | acute coronary syndrome, acute myocardial infarction, peripheral arterial disease, stroke disorder | Shanghai CureGene Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07067775 Comparator | Aug 2025 | acute coronary syndrome | Jiangsu vcare pharmaceutical technology co., LTD | Completed | No outcome recorded |
| Phase 1 | NCT04091074 Comparator | Jan → Dec 2022 | carotid stenosis | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT04945616 Background | Jul → Oct 2021 | thrombotic disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Show all 490 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 49
| Date | Issuer | Release |
|---|---|---|
| 2024-08-12 | Hanmi Pharmaceutical Company Limited | Results 한미약품 ‘심혈관 질환 치료제’ 국제학회서 임상적 유효성 조명 hanmi.co.kr ↗ |
| 2021-02-09 | Sanofi | Regulatory New indication for Plavix® (clopidogrel) now approved in the European Union sanofi.com ↗
The European Commission has approved an additional indication for Plavix ® (clopidogrel) to include its use in combination with aspirin in adult patients with moderate to high-risk Transient Ischemic Attack (TIA) (ABCD2 score ≥4) or minor Ischemic Stroke (IS) (NIHSS 1 ≤3) within 24 hours of either the TIA or IS event. |
| 2020-07-21 | Daiichi Sankyo | Results Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients daiichisankyo.com ↗
The incidence of cerebral cardiovascular events (such as ischemic stroke, myocardial infarction, and other vascular deaths) was lower in the prasugrel group than in the clopidogrel group, thus achieving the primary endpoint in the study. |
| 2016-10-04 | AstraZeneca | Results AstraZeneca reports top-line results from the Brilinta EUCLID trial in patients with peripheral artery disease astrazeneca.com ↗
Brilinta (ticagrelor) did not demonstrate a benefit over clopidogrel in a symptomatic peripheral artery disease (PAD) patient population and therefore did not meet the primary endpoint of the trial. |
| 2014-03-24 | Daiichi Sankyo | Results Subgroup Analysis of PRASFIT-ACS Study Evaluated Impact of Platelet Reactivity on Prevention of Ischemic Events in Perioperative Period of PCI daiichisankyo.com ↗
the incidence of MACE (major adverse cardiovascular events) within 3 days after percutaneous coronary intervention (PCI) in the prasugrel group was 5.6% versus 8.3% for the clopidogrel group |
| 2013-07-12 | Daiichi Sankyo | Results Daiichi Sankyo Announces Phase 3 Study Results (PRASFIT-Elective Study) for the Antiplatelet Agent Prasugrel in Japan daiichisankyo.com ↗
The incidence of the composite primary endpoint (cardiovascular death, non-fatal myocardial infarction, ischemic stroke) was 4.1 percent in the prasugrel group versus 6.7 percent in the clopidogrel sulfate (hereafter, clopidogrel) group. |
| 2013-03-16 | Daiichi Sankyo | Results Daiichi Sankyo Announces Positive Phase 3 Study Results (PRASFIT-ACS) for Prasugrel in Japanese Patients with Acute Coronary Syndrome Undergoing PCI daiichisankyo.com ↗
The incidence of the composite primary endpoint (cardiovascular (CV) death, non-fatal myocardial infarction, ischemic stroke) at 24 weeks in prasugrel patients was 9.4 percent, while 11.8 percent in clopidogrel patients (RR*=23 percent). |
| 2013-03-14 | Daiichi Sankyo | Results Daiichi Sankyo Announces Results of PRASFIT-Elective Study Regarding Use of Prasugrel in Elective Patients with Stable Angina and Chronic Myocardial Infarction Undergoing PCI daiichisankyo.com ↗
The follow-up period for this study has been completed and the anticipated data was obtained. |
| 2012-10-23 | Eli Lilly and Company | Results New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Presented at TCT lilly.com ↗
Effient-treated patients (n=9,404) had a significantly lower adjusted rate of rehospitalization for AMI than Plavix-treated patients (n=74,163) at 30 days (Odds Ratio [OR]: 0.89; p=0.047) and 90 days (OR: 0.90; p= 0.037) following ACS-PCI discharge. |
| 2012-09-21 | Daiichi Sankyo | Results Daiichi Sankyo Announces PRASFIT-ACS Results Regarding Prasugrel in Acute Coronary Syndrome Patients Undergoing PCI daiichisankyo.com ↗
The follow-up period for this study has been completed and the anticipated data was obtained. |
| 2012-08-26 | Daiichi Sankyo | Results Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient(R) (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure daiichisankyo.com ↗
This outcome was not statistically significant (P=0.21). |
| 2012-08-26 | Eli Lilly and Company | Results Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure lilly.com ↗
At 30 months, 13.9 percent of prasugrel patients vs. 16.0 percent of clopidogrel patients experienced the combined primary endpoint of heart attack, stroke or cardiovascular (CV) death in patients under 75 years of age, the primary analysis population (HR=0.91; 95% CI: 0.79-1.05). |
| 2012-08-16 | Wockhardt | Regulatory WOCKHARDT TO LAUNCH GENERIC VERSION OF CLOT BUSTER DRUG PLAVIX® wockhardt.com ↗
Wockhardt is launching the product immediately. |
| 2011-11-16 | Eli Lilly and Company | Results New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI lilly.com ↗
TIMI major non-CABG bleeding events associated with prasugrel as compared to clopidogrel were consistent in the STEMI cohort compared to the overall trial. |
| 2011-07-29 | Sun Pharmaceutical Industries, Inc. | Regulatory Sun Pharma announces USFDA tentative approval for generic Plavix® tablets sunpharma.com ↗
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) for generic version of Plavix®, clopidogrel tablets USP. |
| 2011-05-18 | Boston Scientific Corporation | Results Favorable Clinical Study Results Reported With Dual Anti-Platelet Therapy After LAA Closure With WATCHMAN® Device bostonscientific.com ↗
Results showed that after a mean follow-up of 4.2 months, no cerebrovascular events or device dislodgements occurred. |
| 2011-05-09 | AstraZeneca | Results Health economics substudy of PLATO shows BRILIQUE to be a cost effective treatment versus generic Clopidogrel astrazeneca.com ↗
AstraZeneca today announced new health economics data from a substudy of the PLATO trial showed that treating a broad spectrum of acute coronary syndrome (ACS) patients with BRILIQUE (ticagrelor) was more cost-effective than treatment with generic clopidogrel. |
| 2011-01-25 | Bristol-Myers Squibb | Regulatory Bristol-Myers Squibb and sanofi-aventis Announce U.S. FDA Decision to Grant Pediatric Exclusivity For PLAVIX® bms.com ↗
Bristol-Myers Squibb Company (NYSE: BMY) and sanofi-aventis (EURONEXT: SAN, NYSE: SNY) today announced that the United States Food and Drug Administration (FDA) has granted the companies an additional six-month period of exclusivity to market PLAVIX® (clopidogrel bisulfate). |
| 2010-11-30 | Hanmi Pharmaceutical Company Limited | Regulatory <보도자료> 한미, 개량신약 '피도글' 유럽진출 시동 hanmi.co.kr ↗
한미약품은 지난 25일(현지시간) 영국 의약품안전청(MHRA)이 피도글에 대한 허가승인 결정(approvable)을 최종 통보해왔다고 밝혔다. |
| 2010-11-16 | Eli Lilly and Company | Results Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery lilly.com ↗
New results from an observational substudy from TRITON—TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Effient® (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix® (clopidogrel) (2.3 percent versus 8.7 percent respectively, p=0.016). |
| 2010-09-13 | Eli Lilly and Company | Results Phase II Study Showed Switching ACS-PCI Patients to Effient(R)/aspirin from Plavix(R)/aspirin Regimen Reduced Maximum Platelet Aggregation After One Week lilly.com ↗ |
| 2010-08-29 | AstraZeneca | Results Genetic substudy shows fewer major cardiovascular events with ticagrelor (brilinta) regardless of relevant genetic variability in ACS patients astrazeneca.com ↗
Regardless of the CYP2C19 genotype, the primary outcome occurred less often with ticagrelor versus clopidogrel (interaction p=0.46). |
| 2010-03-16 | AstraZeneca | Results New PLATO Sub-Analysis of CABG Patients Presented at ACC astrazeneca.com ↗
The patients randomised to ticagrelor had a significantly lower rate of total and CV death than those randomised to clopidogrel treatment: |
| 2010-03-15 | Eli Lilly and Company | Results New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy lilly.com ↗
Clopidogrel-treated patients who had two C3435T variants (n=414) had a 66 percent increased risk of experiencing the primary composite endpoint of cardiovascular death, heart attack or stroke compared to clopidogrel-treated patients without the variant (12.9 percent vs. 8.2 percent, HR=1.66; p=0.033). |
| 2010-03-12 | Bristol-Myers Squibb | Regulatory Sanofi-aventis and Bristol-Myers Squibb Announce Important Updates to PLAVIX U.S. Prescribing Information bms.com ↗
Sanofi-aventis U.S. and Bristol-Myers Squibb Company (NYSE: BMY) today announced revisions to the U.S. prescribing information for PLAVIX ® (clopidogrel bisulfate), which include a boxed warning. |
| 2010-01-05 | Eli Lilly and Company | Results New Analysis Showed Effient(R) Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI lilly.com ↗
In the pre-specified analysis of 6,705 patients, treatment with Effient compared with clopidogrel reduced total hospitalization costs over approximately 15 months, not including the cost of study drugs, by $530 per patient. |
| 2009-11-16 | AstraZeneca | Results BRILINTA Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting: Patients with ST-Segment Elevation Myocardial Infarction and Planned Percutaneous Coronary Intervention (PCI) astrazeneca.com ↗
There was an 18% relative reduction in all cause mortality at one year from 6.0 to 4.9% (P=0.04) with ticagrelor over clopidogrel. |
| 2009-11-15 | Eli Lilly and Company | Results Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease lilly.com ↗
In addition, one hour after the loading dose, patients who received prasugrel had 50 percent IPA compared with 13 percent in patients who received clopidogrel. |
| 2009-11-15 | Eli Lilly and Company | Results Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease lilly.com ↗
In addition, one hour after the loading dose, patients who received Effient had 50 percent IPA compared with 13 percent in patients who received clopidogrel. |
| 2009-09-25 | AstraZeneca | Results Brilinta Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial astrazeneca.com ↗
Although patients undergoing invasive procedures are at greater risk of bleeding, these results were achieved without a significant increase in major bleeding compared to clopidogrel (11.5% vs 11.6%, p=0.88). |
| 2009-08-30 | AstraZeneca | Results Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients astrazeneca.com ↗
Ticagrelor is the first investigational antiplatelet that has demonstrated a reduction in CV death versus clopidogrel in patients with acute coronary syndromes (ACS). |
| 2009-08-30 | Bristol-Myers Squibb | Results New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of Plavix® in Acute Coronary Syndrome Patients Undergoing Angioplasty bms.com ↗
The primary end-point (cardiovascular death, heart attack, or stroke at thirty days) for the entire study population (including subpopulations of patients that underwent PCI (70%) or not (30%) examining the difference between the high-dose and standard-dose PLAVIX ® (clopidogrel bisulfate) regimens did not reach statistical significance (4.2% vs. 4.4%, HR 0.95, p=0.37). |
| 2009-05-21 | Eli Lilly and Company | Results Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial lilly.com ↗
In this post hoc analysis, the incidence of non-procedural heart attack in patients treated with prasugrel compared with patients treated with clopidogrel was 2.8 percent vs. 3.7 percent, respectively (p=0.0013). |
| 2009-03-31 | Bristol-Myers Squibb | Results Plavix(®) Plus Aspirin More Effective Than Aspirin Alone in Preventing Major Vascular Events in Patients with Atrial Fibrillation Who Cannot Take Oral Anticoagulants bms.com ↗
The greatest benefit was seen in the reduction of stroke, by 28% (2.4% vs. 3.3% per year, p < 0.001), which is the primary goal of physicians treating patients with atrial fibrillation. |
| 2008-09-03 | Eli Lilly and Company | Results Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel lilly.com ↗
Long-term treatment with prasugrel, continuing after 30 days for up to 15 months, significantly reduced the risk for patients who suffer any form of heart attack by 23 percent compared with clopidogrel (2.9 percent vs. 3.7 percent, p=0.01). |
| 2008-09-03 | Eli Lilly and Company | Results New Crossover Study Shows Prasugrel Significantly Reduced Platelet Aggregation in Patients with Acute Coronary Syndromes Compared with Clopidogrel at High Doses lilly.com ↗
Results of this study, known as the ACAPULCO(1) trial, showed that the 10 mg prasugrel maintenance dose significantly reduced the level of maximum platelet aggregation by 12.9 percent compared to the 150 mg clopidogrel maintenance dose (P<0.001). |
| 2008-08-31 | Eli Lilly and Company | Results Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel lilly.com ↗
In addition, according to this same analysis, the combined rate of cardiovascular death, non-fatal heart attack and non-fatal stroke was reduced by 30 percent in diabetes patients treated with prasugrel compared to those treated with clopidogrel (12.2 percent vs. 17.0 percent, P<0.001). |
| 2008-08-25 | Daiichi Sankyo | Results Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events daiichisankyo.com ↗
New analysis of landmark study showed patients taking prasugrel had lower risk of combined endpoint of recurrent heart attack, stroke or cardiovascular death after first event than those taking clopidogrel |
| 2008-08-21 | Eli Lilly and Company | Results Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events lilly.com ↗
The reduction in recurrent events among prasugrel patients persisted over the duration of the trial (15 months). |
| 2008-06-30 | deCODE genetics | Results DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or With Plavix™ or Aspirin decode.com ↗
DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix™ or Aspirin |
| 2008-03-31 | Daiichi Sankyo | Results Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel daiichisankyo.com ↗
Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel |
| 2008-03-29 | Eli Lilly and Company | Results Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel lilly.com ↗
Prasugrel reduced the relative risk of coronary stent thrombosis (a new clot at the implanted stent site) over clopidogrel by 52 percent (1.13 percent vs. 2.35 percent, p0.0001). |
| 2008-03-05 | Bristol-Myers Squibb | Regulatory New 300mg Loading Dose Tablet For Plavix® Receives Positive Opinion From The European Committee For Medicinal Products (CHMP) bms.com ↗
This positive opinion from the CHMP needs to be ratified by the European Commission in the coming months before final approval. |
| 2007-11-04 | Daiichi Sankyo | Results In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack daiichisankyo.com ↗
A significant reduction in the risk for the composite endpoint favoring prasugrel (60 mg loading dose/10 mg maintenance dose) over clopidogrel (300 mg LD/75 mg MD) was observed as early as three days. |
| 2007-11-04 | Eli Lilly and Company | Results In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack lilly.com ↗
A significant reduction in the risk for the composite endpoint favoring prasugrel (60 mg loading dose/10 mg maintenance dose) over clopidogrel (300 mg LD/75 mg MD) was observed as early as three days. |
| 2006-10-24 | Daiichi Sankyo | Results New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses daiichisankyo.com ↗
Thirty minutes after oral administration, the level of platelet inhibition with a prasugrel 60 mg dose was significantly higher than observed with either loading dose of clopidogrel. |
| 2006-10-23 | Eli Lilly and Company | Results New Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses lilly.com ↗
Thirty minutes after oral administration, the level of platelet inhibition with a prasugrel 60 mg dose was significantly higher than observed with either loading dose of clopidogrel. |
| 2006-03-14 | Eli Lilly and Company | Results Study Shows More Potent and More Reliable Platelet Inhibition with Prasugrel Compared to Clopidogrel Even in Patients With More Reactive Platelets lilly.com ↗
In early phase data announced today, the investigational antiplatelet agent, prasugrel, demonstrated greater and more reliable antiplatelet effect compared to clopidogrel (Plavix(R)) even in patients with increased platelet reactivity. |
| 2005-03-09 | Eli Lilly and Company | Results Results of Early Data Show More Consistent Platelet Inhibition with Prasugrel Compared to Clopidogrel Across Three Distinct Trials lilly.com ↗
In three early- phase trials,(1,2,3) an investigational platelet inhibitor, prasugrel (CS-747, LY640315), demonstrated significantly higher and more consistent inhibition of platelet aggregation (IPA) compared to both placebo and the current standard of care, clopidogrel (Plavix(R)). |
All press releases naming this drug 59 releases
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 816 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | clopidogrel | “Randomization will be stratified by stent type (cobalt-chromium everolimus-eluting stents, platinum-chromium everolimus-eluting stents, and sirolimus-eluting stents with...” PMID 29447787 ↗ Dec 2017806“evaluates the safety and efficacy of clopidogrel and aspirin as an alternative treatment in patients not eligible for recombinant tissue plasminogen activator or any other...” NCT03266731 ↗ “Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors...” NCT03703635 ↗ “The Investigator will decide if to use aspirin or clopidogrel, whereas ticagrelor or prasugrel are not recommended in our study population since no benefit (or even harm) has...” NCT06535568 ↗ “Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice...” NCT00823212 ↗ “Every antiplatelet-naïve patient undergoing an elective procedure will be given 300 mg aspirin and loading dose of one of P2Y12 receptor inhibitors (e.g., 600 mg clopidogrel,...” NCT02601157 ↗ “Five hundred patients with non-cardioembolic AIS presenting within 72 h of symptom onset will be randomized to receive either aspirin 100 mg and cilostazol 200 mg plus EGb 761...” PMID 39528058 ↗ Nov 2024 “Patients may be prescribed single antiplatelet therapy (e.g., aspirin or clopidogrel) or no antithrombotic therapy, strictly at the discretion of the treating physician based...” NCT07609654 ↗ “dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet...” NCT02762864 ↗ “All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if...” NCT01208714 ↗ “Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on...” NCT03287167 ↗ |
| Known as | A brand name for clopidogrel is PLAVIX. | “A brand name for clopidogrel is PLAVIX.” NCT01510327 ↗ |
| Known as | CLO | “Clopidogrel (CLO) is a pro-drug metabolized in the liver by the Cytochrom-P450 system to its active component.” NCT03385538 ↗ |
| Known as | Clop. | “A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders” NCT00642811 ↗ |
| Known as | clopidogrel 75mg tab | “clopidogrel 75mg tab” NCT05567562 ↗ |
| Known as | Clopidogrel = KARDOGREL | “Clopidogrel = KARDOGREL” NCT01493999 ↗ |
| Known as | Clopidogrel Bisulfate | “A number of 352 patients scheduled for elective percutaneous coronary intervention (PCI) with a native coronary stenosis suitable for DES implantation and OCT imaging are...” NCT02140801 ↗6“Clopidogrel bisulfate, a potent antiplatelet agent, has a pivotal role in the prevention and treatment of atherothrombotic disease.” PMID 23328268 ↗ Jan 2013 “plavix : Clopidogrel bisulfate (Sanofi-Aventis) 75mg” NCT00947843 ↗ “clopidogrel bisulfate 97.875mg(75mg as clopidogrel)” NCT02133989 ↗ “Mylan's clopidogrel bisulfate 75 mg tablets” NCT00650169 ↗ “Clopidogrel Bisulfate Tablets 75 mg” NCT00648947 ↗ “Drug: Clopidogrel bisulfate” NCT01447563 ↗ |
| Known as | clopidogrel napadisilate | “Clopidogrel napadisilate, a different salt preparation of clopidogrel, has been developed and approved in Korea and several European countries.” PMID 23328268 ↗ Jan 2013 |
| Known as | Clopidogrel resinate | “Pregrel: Clopidogrel resinate (CKD Pharmaceutical) 75mg” NCT00947843 ↗ |
| Known as | clopidogrel-bisulphate | “Plavix®/Iscover® from Sanofi-Aventis as the original formulation of clopidogrel-bisulphate.” NCT01147133 ↗ |
| Known as | Clopidogrel: Plavix | “Clopidogrel (Plavix)” NCT00799045 ↗7“Clopidogrel (Plavix)” NCT02224274 ↗ “Clopidogrel (Plavix)” NCT02163954 ↗ “clopidogrel = PLAVIX” NCT01147133 ↗ “Clopidogrel (Plavix)” NCT01475552 ↗ “Clopidogrel (Plavix)” NCT03606642 ↗ “Clopidogrel: Plavix” NCT01663038 ↗ “Clopidogrel: plavix” NCT00822536 ↗ |
| Known as | COPIGREL | “COPIGREL® - clopidogrel dosed at 75 mg per tablet” NCT03329261 ↗ |
| Known as | Iscover | “Clopidogrel (Plavix® and/or Iscover®) is an agent inhibiting platelet aggregation involved in clot formation.” NCT00050817 ↗1“Plavix®/Iscover® from Sanofi-Aventis as the original formulation of clopidogrel-bisulphate.” NCT01147133 ↗ |
| Known as | Kardogrel | “generic clopidogrel = Kardogrel” NCT01147133 ↗ |
| Known as | Piece clopidogrel | “patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.” NCT01502943 ↗ |
| Known as | Plavitor | “generic clopidogrel (Plavitor® )” NCT02060786 ↗ |
| Known as | Plavix | “Clopidogrel (Plavix) is currently a widely used thienopyridine that has been used for the treatment of patients presenting with the acute coronary syndrome and patients...” NCT00827346 ↗36“One group took acetylsalicylic acid (ASA) 80 mg once daily and clopidogrel 75 mg that is produced by Sanofi company available in market as Plavix once a day” NCT05858918 ↗ “Following a baseline punch biopsy, all subjects will then receive oral clopidogrel (Plavix®) over a period of approximately 3 to 4 days.” NCT01603342 ↗ “Participants that are not carriers of the CYP2C19 gene will receive either Plavix monotherapy or dual therapy with Plavix and Aspirin.” NCT07602257 ↗ “Aspirin Enteric-coated Tablets (Bay Aspirin) 100mg once a night+Clopidogrel Sulfate Tablets (Plavix) 75mg once daily.” NCT05902000 ↗ “Clopidogrel (Plavix® and/or Iscover®) is an agent inhibiting platelet aggregation involved in clot formation.” NCT00050817 ↗ “Patiënt interventional treatment, with dabigatran + clopidogrel (plavix) 75mg once daily up to 12 months.” NCT04688723 ↗ “versus co-administration of Plavix (clopidogrel) and Astrix (aspirin) in healthy male volunteers.” NCT01657071 ↗ “Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.” NCT01339026 ↗ “Clopidogrel (Plavix) 75 mg qd, 2 weeks; followed with Ticagrelor (Brilinta) 90 mg bd, 2 weeks” NCT02459288 ↗ “Aspirin and Clopidogrel (Plavix) for 1-month post-procedure followed by Aspirin indefinitely.” NCT07076082 ↗ |
| Known as | Plavix (clopidogrel) | “Plavix (clopidogrel)” NCT01823510 ↗ |
| Known as | plavix : Clopidogrel bisulfate (Sanofi-Aventis) 75mg | “plavix : Clopidogrel bisulfate (Sanofi-Aventis) 75mg” NCT00947843 ↗ |
| Known as | pregrel | “pregrel is a generic brand name of clopidogrel” NCT00947843 ↗ |
| Known as | Pregrel: Clopidogrel resinate (CKD Pharmaceutical) 75mg | “Pregrel: Clopidogrel resinate (CKD Pharmaceutical) 75mg” NCT00947843 ↗ |
| Known as | SR25990 | “Drug: Clopidogrel (SR25990)” NCT00396877 ↗5“clopidogrel (SR25990)” NCT00821834 ↗ “Clopidogrel (SR25990)” NCT00115375 ↗ “clopidogrel (SR25990)” NCT00050817 ↗ “Clopidogrel (SR25990)” NCT00714961 ↗ “clopidogrel (SR25990)” NCT00862420 ↗ |
| Known as | SR25990C | “clopidogrel (SR25990C)” NCT00249873 ↗ |
| Action | Inhibit | “(an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner)” NCT00007683 ↗ |
| Modality | Small molecule | “clopidogrel, a thienopyridine inhibitor of the platelet P2Y12 adenosine diphosphate (ADP) receptor” NCT01012193 ↗ |
| Route | Oral | “Clopidogrel is an oral antiplatelet agent that has been shown to prevent strokes and heart attacks.” NCT00004564 ↗ |
| Target | P2RY12 | “they act by inhibiting the the P2Y12 ADP receptor on platelets.” NCT00611286 ↗ |